<SEC-DOCUMENT>0001628280-23-035729.txt : 20231031
<SEC-HEADER>0001628280-23-035729.hdr.sgml : 20231031
<ACCEPTANCE-DATETIME>20231031162541
ACCESSION NUMBER:		0001628280-23-035729
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231031
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20231031
DATE AS OF CHANGE:		20231031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			X4 Pharmaceuticals, Inc
		CENTRAL INDEX KEY:			0001501697
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				273181608
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38295
		FILM NUMBER:		231364860

	BUSINESS ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134
		BUSINESS PHONE:		857-529-8300

	MAIL ADDRESS:	
		STREET 1:		61 NORTH BEACON STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Arsanis, Inc.
		DATE OF NAME CHANGE:	20100920
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>xfor-20231031.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:985385aa-7e1e-454b-a800-9291f5721a92,g:f001a0b3-d3d2-429d-9de4-7a156a61ec58,d:ded6143976c747a9818cb4321dbdd632--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>xfor-20231031</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001501697</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="xfor-20231031.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501697</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-31</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ided6143976c747a9818cb4321dbdd632_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.844%"><tr><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.108%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.068%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"><tr><td style="width:1.0%"></td><td style="width:48.183%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">FORM  </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></td></tr><tr style="height:8pt"><td colspan="6" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">October 31, 2023</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.603%"><tr><td style="width:1.0%"></td><td style="width:22.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.600%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">X4 PHARMACEUTICALS, INC.</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.793%"><tr><td style="width:1.0%"></td><td style="width:32.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38295</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">27-3181608</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.373%"><tr><td style="width:1.0%"></td><td style="width:20.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">61 North Beacon Street,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">4th Floor</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Boston,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-10">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">02134</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">857</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">529-8300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">_______________________________________________________________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule  13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.252%"><tr><td style="width:1.0%"></td><td style="width:34.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">XFOR</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#167;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#167;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">240.12b-2 of this chapter).          </span></div><div style="padding-left:360pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Emerging growth company&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ided6143976c747a9818cb4321dbdd632_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 8.01&#160;&#160;&#160;&#160;Other Events</span></div><div><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On October 31, 2023, X4 Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing that the  U.S. Food and Drug Administration (&#8220;FDA&#8221;) accepted for filing the Company&#8217;s New Drug Application (&#8220;NDA&#8221;) for once-daily, oral mavorixafor to trea</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">t</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> individuals aged 12 and older with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency. The FDA granted Priority Review of the mavorixafor NDA and assigned a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) target date of April 30, 2024. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.637%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline" href="ex_991xxforxoct312023.htm">Press Release, dated October 31, 2023.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ided6143976c747a9818cb4321dbdd632_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span><br/></span></div><div style="padding-left:252pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.924%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">X4 PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  October 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adam Mostafa</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adam Mostafa</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_991xxforxoct312023.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i951bca54d4c74515bea6b7201625f957_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#2f5496;font-family:'Calibri Light',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 99.1</font></div><div style="margin-top:12pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:86px;margin-bottom:5pt;vertical-align:text-bottom;width:111px"></div><div><font><br></font></div><div style="padding-left:6.85pt;padding-right:6.85pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:130%">FDA sets a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:130%">If the NDA is approved, company eligible to receive a Priority Review Voucher (PRV) resulting from mavorixafor&#8217;s rare pediatric designation in WHIM syndrome</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:130%">NDA supported by positive results from global, pivotal 4WHIM Phase 3 clinical trial</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BOSTON, October 31, 2023 &#8211; X4 Pharmaceuticals </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Nasdaq&#58; XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the United States Food and Drug Administration (FDA) has accepted for filing the company&#8217;s New Drug Application (NDA) for once-daily, oral mavorixafor to treat individuals aged 12 and older with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency. </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The FDA granted Priority Review of the mavorixafor NDA, establishing a goal of six months review from the date of acceptance and assigning a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2024.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The FDA&#8217;s acceptance of our mavorixafor NDA with priority review represents yet another significant step forward towards a potential treatment for those with WHIM syndrome, a rare disease for which there are currently no approved therapies,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. &#8220;We look forward to working closely with the FDA throughout the NDA review process with the goal of bringing mavorixafor </font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to people with WHIM syndrome as quickly as possible</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mavorixafor is an investigational small-molecule antagonist of the CXCR4 receptor being developed as a once-daily oral therapy for WHIM syndrome and certain chronic neutropenic disorders. For the WHIM syndrome indication, mavorixafor has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease (RPD) Designation in the U.S., and Orphan Drug Status in both the U.S. and European Union. </font><font style="background-color:#ffffff;color:#292e32;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon FDA approval of a product with RPD designation, the sponsor can receive a Priority Review Voucher that can be used to obtain priority review for a subsequent application or sold to another drug sponsor.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The NDA is supported by the results of the global, pivotal, 4WHIM Phase 3 clinical trial of once-daily, oral mavorixafor in individuals with WHIM syndrome. The 4WHIM trial met its primary endpoint of time above threshold for absolute neutrophil count (TAT-ANC) vs. placebo (p&#60;0.0001), a key secondary endpoint, and was generally well tolerated in the trial, with no treatment-related serious adverse events reported and no discontinuations for safety events. The 4WHIM data also revealed that mavorixafor treatment resulted in reductions in the rate, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">severity, and duration of infections in trial participants versus placebo. These and additional 4WHIM Phase 3 data were published in oral presentations at the annual meetings of both the Clinical Immunology Society (CIS) and European Hematology Association (EHA).</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About WHIM Syndrome</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHIM syndrome is a rare, inherited, combined immunodeficiency disease caused by reduced mobilization and trafficking of white blood cells from the bone marrow due to over-signaling of the CXCR4&#47;CXCL12 pathway. WHIM syndrome is named for its four common clinical findings&#58; Warts, Hypogammaglobulinemia, Infections, and Myelokathexis, although not all patients experience all symptoms, and not all symptoms are required for a diagnosis. People with WHIM syndrome characteristically have very low blood levels of neutrophils (neutropenia) and lymphocytes (lymphopenia), and as a result, experience frequent, recurrent infections with a high risk of lung disease and refractory warts from underlying human papillomavirus (HPV) infection. Those with WHIM syndrome may also have limited antibody production due to low levels of immunoglobulin and an increased risk of developing certain types of cancer. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About the 4WHIM Phase 3 Clinical Trial</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The 4WHIM Phase 3 clinical trial was a global, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of oral, once-daily mavorixafor in people with genetically confirmed WHIM syndrome. The trial enrolled 31 participants aged 12 and older who received either mavorixafor (n&#61;14) or placebo (n&#61;17) orally once daily for 52 weeks. An open-label extension phase of the clinical trial is ongoing (NCT03995108).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">About X4 Pharmaceuticals </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company driven to improve the lives of people with rare diseases of the immune system. Our lead clinical candidate is mavorixafor, a small molecule antagonist of chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy across a variety of immunodeficiencies, including WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome and certain chronic neutropenic disorders. Following successful completion of a global, pivotal, Phase 3 clinical trial, we are seeking U.S. approval of oral, once-daily mavorixafor for the treatment of people aged 12 years and older with WHIM syndrome. We are also currently planning a Phase 3 clinical program evaluating mavorixafor in certain chronic neutropenic disorders. We continue to leverage our insights into CXCR4 and immune system biology at our corporate headquarters in Boston, Massachusetts and at our research center of excellence in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.</font></div><div><font><br></font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, statements regarding the timing and potential impact of FDA acceptance and priority review of X4&#8217;s NDA for mavorixafor for the treatment of individuals with WHIM syndrome&#59; and mavorixafor&#8217;s potential to be the first therapy for WHIM syndrome</font><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, risks of obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections or the risk that the FDA will require additional trials or data&#59; the potential inability to raise sufficient capital to fund ongoing operations as currently planned or to obtain financings </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on terms similar to those arranged in the past&#59; the ability to service indebtedness and otherwise comply with debt covenants&#59; outcomes or trends from competitive studies&#59; the timing and outcomes of clinical studies of mavorixafor&#59; general economic conditions&#59; and other risk and uncertainties, including those described in the section entitled &#8220;Risk Factors&#8221; in X4&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 10, 2023, and in other filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Contacts&#58;</font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Daniel Ferry (investors)</font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Managing Director, LifeSci Advisors</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">daniel&#64;lifesciadvisors.com</font><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div><font style="color:#0a0a0a;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(617) 430-7576</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Brett Whelan (media)</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LifeSci Communications</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">bwhelan&#64;lifescicomms.com </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>xfor-20231031.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:985385aa-7e1e-454b-a800-9291f5721a92,g:f001a0b3-d3d2-429d-9de4-7a156a61ec58-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xfor="http://www.x4pharma.com/20231031" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.x4pharma.com/20231031">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20231031_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="xfor-20231031_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.x4pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>xfor-20231031_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:985385aa-7e1e-454b-a800-9291f5721a92,g:f001a0b3-d3d2-429d-9de4-7a156a61ec58-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_fece4bd8-3bce-46d3-84e7-00457823bd6f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_852bf29a-7bd2-4c08-af31-35c25eb9aaa7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a6969689-10a6-40ea-9c66-878d2570b613_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8f1d4b98-164d-4a29-9ea7-c4bba760f2db_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1669f082-2a3d-438d-89c6-f718a7493f9a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_30316318-c9f4-4cdf-90d7-9ca13aa171ed_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_a9c563be-17ab-4ebc-b945-79e050bc4e1f_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_3e7250e1-190d-4e7c-ac31-35b650f69c6b_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d2501f20-d544-4ab4-b52b-855cd20d2bef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_868413a0-ef22-4950-9302-e3365771ef08_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1a5046a7-97db-4e8d-9f92-0b9b6f9efe98_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_893a2bcc-5bbd-4c00-9d27-dd43bb4f9a1c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_35e00fe6-50bb-4c55-9916-11b9a64f3477_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b850d039-8cf6-4545-9c9e-2cfbf50d37f0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e81834df-ee8a-4b92-976f-66f9a43a867c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_556872b8-d59e-4d4d-ac9e-b0453ec5587f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_1b38e718-d4f1-4e4d-a307-1c0e125b7ecd_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d9581004-6cad-4e38-abce-40292599527f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_602b2d91-68c1-44c9-b88a-9583f723ab0e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_490694f8-9d78-4462-80ea-b84e8be881fa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_52ecdfdc-3268-4d9b-859d-c116b79d14b0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e6c56666-dd11-4d84-ba5f-63728eb99a04_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_db86d47b-dcc5-4f1c-9997-6b68c1be02fc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_5e8cbfca-ab29-49ac-b026-30e5dc44dbb6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>xfor-20231031_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:985385aa-7e1e-454b-a800-9291f5721a92,g:f001a0b3-d3d2-429d-9de4-7a156a61ec58-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.x4pharma.com/role/Cover" xlink:type="simple" xlink:href="xfor-20231031.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.x4pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f6f15d4d-a88c-450e-a3b5-83c2200d39d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_DocumentType_f6f15d4d-a88c-450e-a3b5-83c2200d39d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b716421e-07e0-43af-86da-eca1adbc6680" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_DocumentPeriodEndDate_b716421e-07e0-43af-86da-eca1adbc6680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ce679e6a-eaf7-4d42-b9ce-9daa7c70d14b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityRegistrantName_ce679e6a-eaf7-4d42-b9ce-9daa7c70d14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7f9eba3a-7516-439b-9b8d-8be59ee262f3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7f9eba3a-7516-439b-9b8d-8be59ee262f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_54af53c7-79fb-4ded-a0f3-8b4ce502a082" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityFileNumber_54af53c7-79fb-4ded-a0f3-8b4ce502a082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d75ddbe8-65a0-4dff-bef3-8d5e81adf538" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityTaxIdentificationNumber_d75ddbe8-65a0-4dff-bef3-8d5e81adf538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9f2d1654-1746-45b6-bfb3-528ae9a36a10" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityAddressAddressLine1_9f2d1654-1746-45b6-bfb3-528ae9a36a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_69e4c1e0-9320-4d2a-8508-a7f04f69b2cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityAddressAddressLine2_69e4c1e0-9320-4d2a-8508-a7f04f69b2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f7d46271-7353-40f6-8323-53d935df3163" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityAddressCityOrTown_f7d46271-7353-40f6-8323-53d935df3163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0ed45edb-ab39-4dff-ac6f-13f7b6218ecd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityAddressStateOrProvince_0ed45edb-ab39-4dff-ac6f-13f7b6218ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b3591492-5a05-407c-91fd-cb9831b8ead9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityAddressPostalZipCode_b3591492-5a05-407c-91fd-cb9831b8ead9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8af7e229-c915-4cae-91f5-ad6bccc11a52" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_CityAreaCode_8af7e229-c915-4cae-91f5-ad6bccc11a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1f7b4f56-7b89-4aeb-9a5e-4ac3e25d8f2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_LocalPhoneNumber_1f7b4f56-7b89-4aeb-9a5e-4ac3e25d8f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_b5837db8-74d0-4bee-bcc1-f8dbd39bc145" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_WrittenCommunications_b5837db8-74d0-4bee-bcc1-f8dbd39bc145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_acd34dbd-1bc6-4586-911d-1f0c52fb66fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_SolicitingMaterial_acd34dbd-1bc6-4586-911d-1f0c52fb66fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_f908d318-4e82-423e-81ce-39b0ce6500ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_PreCommencementTenderOffer_f908d318-4e82-423e-81ce-39b0ce6500ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_e27fd491-d970-469c-b153-15b2e1cc5e70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_e27fd491-d970-469c-b153-15b2e1cc5e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4a65c384-9d72-44fd-80b6-988009c787c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_Security12bTitle_4a65c384-9d72-44fd-80b6-988009c787c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_abea94c0-599b-435d-824b-1c409a42fa14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_TradingSymbol_abea94c0-599b-435d-824b-1c409a42fa14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a94b1d73-ab4d-460d-bece-ba686c4c6c74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_SecurityExchangeName_a94b1d73-ab4d-460d-bece-ba686c4c6c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8606f15b-863f-4baa-b895-811f11ac81f4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityEmergingGrowthCompany_8606f15b-863f-4baa-b895-811f11ac81f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_d2782539-5e29-4fab-b4fa-92092bce2b2b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityExTransitionPeriod_d2782539-5e29-4fab-b4fa-92092bce2b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_179c1d36-84ef-446d-9684-99c8c3f2d83a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_EntityCentralIndexKey_179c1d36-84ef-446d-9684-99c8c3f2d83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c2190c63-0df5-4949-96ba-7af2a368def0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_598bc050-41ae-4e0a-a39f-f0ef1bf63b05" xlink:to="loc_dei_AmendmentFlag_c2190c63-0df5-4949-96ba-7af2a368def0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #% /\# 2(  A$! Q$!_\0
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MC(]:* "BBB@ HHW#UHS0 4444 %%%&: "BC(SC-!('4T %%%% !11D8S1F@
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M8N1$>C" $R-GMM4YQQ7D8CB2:J6HPT[O_(^KRS@"KB;1J-N3^S!7?_!/%?V
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M2;AG%#,!U- #"5(Q7S;_ ,%!_P!I71/A?X!F^%ECI%KJ6K>(K-XY(KI0\=I
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MGMK7XB>/--T:2\5GM5OKH1F55(!(SUQD?G6"/VN?V9">?CAX=_\ !@M?,?\
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MX+N>U?\ !-W]E>"SL8_V@/'6FV\DMTO_ !3=M-$2T"9(-QSQEA]T@'"\Y^;
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MX(Y&11=:_H5E>+IE]K-K#</"TJ02W"J[1K]YPI.=H[GH*^'_ (R>%] \#_\
M!:#]EKP7X4TY++2](^$/BNRTVSC)*P6\4$"1Q@DDD*J@<G/%/_:<T'1O$_\
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M'<6LZR1M@D'#*2#@@CZBF:#XD\.^)[5K_P -Z]9ZA LGEO-8W23(K8!VDJ2
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140138911926032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">X4 PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3181608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61 North Beacon Street,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">4th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">529-8300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XFOR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>xfor-20231031_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="xfor-20231031.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501697</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001501697</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-10-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">X4 PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38295</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">27-3181608</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">61 North Beacon Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">4th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Boston,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">02134</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">529-8300</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">XFOR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ -(-?5ZK$(A8S 0  (@(   \
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M4$L! A0#%     @ -(-?5[3\IR;N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ -(-?5YE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  T@U]7FSR^\V($   D$0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ -(-?5Y^@&_"Q @  X@P
M  T              ( !I0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  T
M@U]7EXJ[',     3 @  "P              @ &!#P  7W)E;',O+G)E;'-0
M2P$"% ,4    "  T@U]7JL0B%C,!   B @  #P              @ %J$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ -(-?5R0>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ -(-?5V60>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="xfor-20231031.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.x4pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="xfor-20231031.htm">xfor-20231031.htm</File>
    <File>xfor-20231031.xsd</File>
    <File>xfor-20231031_lab.xml</File>
    <File>xfor-20231031_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "xfor-20231031.htm": {
   "nsprefix": "xfor",
   "nsuri": "http://www.x4pharma.com/20231031",
   "dts": {
    "inline": {
     "local": [
      "xfor-20231031.htm"
     ]
    },
    "schema": {
     "local": [
      "xfor-20231031.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "xfor-20231031_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xfor-20231031_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "report": {
    "R1": {
     "role": "http://www.x4pharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xfor-20231031.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "xfor-20231031.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.x4pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-035729-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-035729-xbrl.zip
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M\QNM 7._J@,LH($BA$T.HUJ]<$QZS \?4)A8B"(G5>T/TN<^+DH>PPJ5+/!
MR#($.0]'OJ0!"T>Q/R$QE3SN3U3+M$'8 \G2+#B&!3.IPA'0 04*)EE9/_2A
M<VR'.(]C^"BNO];RWPVC\UO]SX)+8"U&SD9!&AN*%V%P+PS]'@4^29#6=&=P
M,))9JSC.\=.-854@,^T.1C3;'XEFCF5U1CXCCE5*!?7DN!.><CHP*Z1UT2&6
MC:FITJ*IWG>F=T,POS"?X.X2%@"L C\OQTMK<_RQ+S),.UMDM^E0@! S')\[
M53;EMV/H2<WWQ_(;P5#'\;Z6.N^)UD1<]_N(<_*QOKPVZZ%/S9WI]$6M-QU/
MLPYZA_D$D=1]]Z)HQ_&(B0T$4MF^0(AI,\TY</-))*W[MX6.,V8XV4^9@!TY
M6G:D5FEQNK\"G];;3M\XX^#H5FFC.PRVHU<KFQVX>#Z^[U1>_W2(Y>BU#?,8
MSY=5MY = <Z:9C[._IW.G-SBA>_D0+,[("ZX,O%W?,S@5E#EDW<GPU[H'VPS
M\+7WO+A*CSPJQ6#9#@26]F' X9M'<[S.>8F-KOSL'V_6P-W)!C8QK9Y::E,H
M407?%*" 2O:%[M<C$E%![JD_8N2?AFX8)HGP@OY@ZP>LOCN1I(L\6>-3>=0*
MC2\7UYT?O-Z*^F<(-CE<_A1LHW693W99!AAC ')7-/;H7\D2(9=4?&62?/S8
M>CD[LUYH?LM<7'!?%-!H!QZZ 8ST)L1582J DE_!O#)UX.I)#(G'!$8(/@2B
MS3MR)\('.4!O(L*X$HV)Q_K0A3J*GL0SC!)9O+OU>&7+)@=O<U5I^>S1/:H<
M;V4$^=BO0CD9C[@ZNQ_AV7T,^2:NL=73K"4L7';][7OG)?JBC^R:X:9.IC\K
M';+4]FF8W:_;92,S?SS \V/PC3*K.Y@6.5^^W-*#USN4^+HY[VPBOZEYM))I
MO/P:DKDRWK&GP>H7Y:JB"NW^,[84<W-+#3-?B.L/P.PRG[GX/%P0JG#$*&:J
M%G AS1[@TV5<A2B25XN0Z:HO?X*=JV?ET(0',#4H$>R>Q] .C#D-7 R=4M?%
M _I8&=\"\ZCPXB1OX*V*A=@'=!H+F357^MS%@=WHKY6<1DZU:JDZ;!"<>N,
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MC08! "P7 98<4*E0$_FD=W5R$0)> \A%SL3HCC0]4'B%_13*.DA[N3AK3GL
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MPW(%X^W:?3_;0"O8K?5R\@102P,$%     @ -(-?5[=D?TSW"@  ^F0  !4
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M)W$ ,/[4B5Z<R+%S<CB=1X'-^V()/]^L/-2YDBXI$3*2V>01>< ]D2:!OLL
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M;+,?!R-N5@Z4\94AN*JA)1@PL>WNW+8W_>L/"?W(DZ4F"F90"],^!"* &!:
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M;W(M,C R,S$P,S$N>'-D4$L! A0#%     @ -(-?5[=D?TSW"@  ^F0  !4
M             ( !9B,  'AF;W(M,C R,S$P,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( #2#7U=H*.X7!0<   \U   5              "  9 N  !X9F]R+3(P
D,C,Q,#,Q7W!R92YX;6Q02P4&      4 !0!+ 0  R#4

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
